LBL-007 (anti-LAG3 monoclonal antibody):

'Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy'. Published in MABS 2019 (paper).

LBL-024: a bispecific antibody:

'An anti-PD-L1 and 4-1BB bispecific antibody with highly differentiated binding affinity, shows anti-tumor efficacy in a mouse tumor model' was accepted as a poster by 2021-AACR

LBL-015: a bispecific fusion protein:

'A novel anti-PD-1 fused with TGF-βR2, shows a great anti-tumor activity in a mouse MC38 model' was accepted as poster by 2021-AACR

LBL-007 (anti-LAG3 monoclonal antibody):

'Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors' was accepted as a poster by 2021-ASCO

LBL-019 (anti-TNFR2 monoclonal antibody) :

'LBL-019, a novel anti-TNFR2 antibody, shows a potent anti-tumor efficacy in a mouse MC38 model' was accepted as a poster by 2022 AACR